Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024
April 09, 2024 08:00 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel...
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
April 03, 2024 08:00 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel...
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
March 27, 2024 08:00 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel...
Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
March 18, 2024 08:00 ET
|
Aligos Therapeutics
Screening of subjects has begun at clinical study sitesThe Phase 2a study is being led by Principal Investigator, Dr. Stephen HarrisonAligos anticipates dosing the first subject in Q2 2024 with...
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
March 12, 2024 16:05 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel...
Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024
March 05, 2024 16:05 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel...
Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024
February 26, 2024 08:00 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics...
Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024
February 20, 2024 08:00 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics...
Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments
February 13, 2024 08:00 ET
|
Aligos Therapeutics
Jordyn Tarazi joins as Vice President, Investor Relations and Corporate Communications Nikhil Aneja, CPA, CA appointed as Vice President, Finance SOUTH SAN FRANCISCO, Calif., Feb. 13, 2024 (GLOBE...
Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)
December 07, 2023 16:05 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...